Is Gilead Sciences, Inc. Getting Too Greedy?

Gilead is taking some heat for its $84,000 drug Sovaldi. Is the biotech greedy -- or just trying to earn a fair profit from its investment?

Jan 28, 2014 at 6:00PM

Is Gilead Sciences (NASDAQ:GILD) just a greedy large corporation, or a biotech bringing hope for millions of hepatitis C patients and making a reasonable profit for doing so?

That question has been raging over the last couple of months after Bloomberg reported that the nation's largest pharmacy benefits manager, Express Scripts, could take a hard line with the high costs of new hepatitis C drugs hitting the market. Express Scripts' Chief Medical Officer Steven Miller was quoted as saying that his company could recommend less-expensive drugs that weren't as convenient as higher-priced drugs if there was no demonstrated improvement in outcomes.

Gilead priced its new hep C drug Sovaldi at $84,000 for a 12-week treatment.Does that amount really reflect corporate greed -- or is it a fair price for the value provided to patients?


Source: Gilead Sciences.

Comparison shopping
Any discussion of pricing should include a little comparison shopping. Gilead faces a handful of major competitors with products already on the market for treatment of hepatitis C.

Vertex Pharmaceuticals (NASDAQ:VRTX) gained FDA approval in 2011 for Incivek. While Vertex started off Incivek at around $49,000 per 12-week treatment, the price now stands closer to $66,000. It's probably no coincidence that after gaining regulatory approval for Olysio last November, Johnson & Johnson (NYSE:JNJ) pegged the price of its hep C drug at nearly the exact same level.

Is Sovaldi's 27% premium over Incivek and Olysio warranted? Both newer drugs appear to be superior to Incivek, reflected in a continued slide in sales for Incivek and Vertex's decision to cut positions late last year.

However, Sovaldi also claims a couple of significant advantages over Olysio. First, Gilead's drug won approval for treating hepatitis C genotypes 1 through 4, while J&J gained approval only for genotype 1. Second, for genotype 1a (the most common form of hep C in the U.S.), Sovaldi boasts a 92% cure rate compared to 84% for Olysio.

The market speaks
If we just looked at those comparisons, we could conclude that Sovaldi might be a little overpriced compared to J&J's Olysio but not ridiculously so. Of course, some could also argue that Olysio itself is priced too highly.

The ultimate answer to what price is right, however, can usually be found in the market. If a price is truly too high for the value provided by a product, many buyers will turn to another alternative. So, what is the market saying so far about Sovaldi's price?

Total prescriptions for Sovaldi are coming in higher than analysts predicted -- and not just by a small amount. For the week ending Jan. 17, total prescriptions were 2.8 times higher than consensus estimates. Leerink and ISI Group think that Sovaldi could be on pace to blow away previous sales projections.

Gilead acknowledges it will take a few more months to gain official approval from some payers and PBMs. However, the company says most plans include Sovaldi in their formularies. For now, at least, the market seems to be voicing its opinion that Gilead's price isn't too high.  

More comparisons
What sometimes gets lost in the discussion about the high costs of new drugs are the potential costs that could be incurred without those drugs. For example, hepatitis C is the leading cause of liver transplants. In 2011, a liver transplant cost nearly $580,000 on average. 

Also, as Express Scripts and other PBMs focus on controlling prescription drug costs, one of their major focus areas is on adherence to medication schedules. Drugs that are more convenient for patients to take tend to have higher adherence rates, thereby lowering overall costs. That could give Gilead an edge in its effort to win support from payers and PBMs with the Sovaldi/ledipasvir all-oral combo on the way.

Is Gilead being greedy by pricing Sovaldi higher than other drugs? Maybe. However, it's also true that the biotech has developed a product that could help pave the way for millions to be cured of hepatitis C -- along with other current and forthcoming drugs from rivals. If the total costs from this all-too-common disease are lessened, I'd say the price is right.

An idea for you to make money for a price you can't beat
The Motley Fool's chief investment officer has selected his No. 1 stock for 2014. It's one of those stocks that could make you rich. And we're ready to give this great investing idea to you for the grand sum of... nothing. That's right, you can find out which stock it is for free in the special report "The Motley Fool's Top Stock for 2014." Just click here to access the report and find out the name of this under-the-radar company.

Fool contributor Keith Speights owns shares of Express Scripts and Gilead Sciences. The Motley Fool recommends Express Scripts, Gilead Sciences, Johnson & Johnson, and Vertex Pharmaceuticals. The Motley Fool owns shares of Express Scripts and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers